Unlocking the Potential Of Rapamycin
Date & Time:
September 16, 12:00 PM EDT
Webinar: Details provided upon RSVP approval
About the Event:
Rapamycin was first discovered on Easter Island in 1972. It has shown promise in multiple indications from cognition to transplant rejection to cancer. The drug has even been demonstrated to delay the effects of normal aging. Unfortunately the use of rapamycin has been limited by the drug’s low bio-availability, significant toxicity, and large interpatient pharmacokinetic variation.
Emtora Biosciences is developing a technology that unlocks rapamycin’s immense potential. eRapa is a proprietary, patented, micro-encapsulated formulation of rapamycin that improves the original drug’s absorption and safety, allows for a lower therapeutically effective dose, and provides for targeted delivery to the site of active disease.
- Emtora has successfully completed a Phase 1 study of eRapa in prostate cancer patients.
- The company is now initiating two, separate Phase 2 trials in patients with non-muscle invasive bladder cancer and a rare genetic condition known as Familial Adenomatous Polyposis (FAP).
- FAP has enabled Emtora to secure Orphan Drug Designation from the FDA, providing it with an accelerated approval pathway and market exclusivity.
- The company’s Phase 2 studies are backed by ~$6M in non-dilutive grant funding.
- Topline data from the company’s Phase 2 study in FAP is expected as early as the third quarter of next year.
Join Emtora’s executive team for our exclusive webinar to learn more about how the company is unlocking rapamycin’s potential with its proprietary eRapa,
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.